Search Within

Arlyn Apollo

  1. "Biostatistics Service"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Biostatistics Service (6)
  2. Department of Medicine (6)
  3. Epidemiology and Biostatistics (6)
  4. Genitourinary Oncology Service (6)
  5. Solid Tumor Oncology Division (6)
  6. Weinberg Fellows (4)

More Groups

People
  1. Han Xiao (4)
  2. Chung-Han Lee (3)
  3. Dean Bajorin (3)
  4. Gopakumar Iyer (3)
  5. Irina Ostrovnaya (3)
  6. Jonathan Rosenberg (3)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2018 (1)
  6. 2015 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Annals of Oncology (1)
  3. Cancer (1)
  4. European Urology Open Science (1)
  5. The Oncologist (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Oxford University Press (2)
  3. Elsevier BV (1)
  4. Wiley Blackwell (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial
    Journal Article

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H.; Quinlan, C.; Teo, M. Y.; Lee, C. H.; Aggen, D.; Zimmerman, D.; McHugh, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
    Journal Article

    Feldman, D. R.; Ged, Y.; Lee, C. H.; Knezevic, A.; Molina, A. M.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Murray, S.; Tickoo, S. K.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial
    Meeting Abstract

    Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: A large single-institution experience
    Journal Article

    Bambury, R. M.; Benjamin, D. J.; Chaim, J. L.; Zabor, E. C.; Sullivan, J.; Garcia-Grossman, I. R.; Regazzi, A. M.; Ostrovnaya, I.; Apollo, A.; Xiao, H.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save